TAE Life Sciences is at the forefront of innovation in radiation therapy, leveraging cutting-edge technology to revolutionize the landscape of cancer therapeutic solutions. Pioneering the convergence of accelerator-based neutron beam technology and proprietary boronated drugs, the company is dedicated to transforming cancer care by introducing a biologically targeted radiation therapy solution for a Boron Neutron Capture Therapy (BNCT) platform.

 

The Next Frontier in Cancer Therapy

BNCT differs radically from other radiation therapy and shows promise in becoming a new treatment option with the potential for fewer side effects. Unlike other cancer radiation treatments that use physical targeting of tumors, BNCT uses biological targeting precision through uptake of a benign boron-10 (10B) target drug, and neutron beam for activation. Either component on its own does not produce a therapeutic dose, but the combination releases a cancer killing localized dose that is deposited only in the cell that contains 10B.  With selective 10B uptake in tumor cells, this permits cancer destruction on a cell-by-cell basis while sparing adjacent normal tissue cells.

 

Alphabeam: A Transformative Neutron Source Designed for a Hospital Environment

At the heart of TAE Life Sciences' BNCT solution is Alphabeam, a compact, particle accelerator-based neutron source. This state-of-the-art technology represents a paradigm shift in BNCT, that has turned a once impractical treatment modality that required the use of a nuclear reactor into a viable treatment modality that can be safely incorporated into any cancer center.

 

Alphabeam features a variety of components that work together to convert negative Hydrogen ions into a precise low-energy neutron beam. This neutron beam plays a pivotal role in BNCT, by creating a reaction with Boron10 that is absorbed by cancerous tumor cells via the administration of boronated drugs to the patient. The neutrons accumulate in the nucleus of the cancer cell and interact with the Boron10 to create a highly energized reaction that breaks up the Boron atom, releasing a Lithium particle and deadly alpha particle. This ultra-precise therapy kills tumor cells with unparalleled accuracy, and nearly eliminates the risk of collateral damage to surrounding healthy tissues.

 

Alphabeam's key features include:

• Precision Targeting: Alphabeam precisely directs neutron beams to cancerous cells, maximizing therapeutic impact while minimizing harm to adjacent tissues.

• Enhanced Penetration: The system's neutron beams penetrate deep-seated tumors, accessing regions previously deemed difficult or impossible to treat.

• Optimized Efficacy: Alphabeam's controlled neutron release ensures effective tumor eradication, elevating therapeutic outcomes.

 

Proprietary Boronated Drugs: Small Molecules and Beyond:

Complementing Alphabeam and TAE Life Science’s BNCT treatment platform, TAE Life Sciences has developed a suite of proprietary boronated drugs, including Boronotyrosine (BTS), an extremely promising borylated amino acid mimetic that offers significant advantages over traditional BNCT drugs like Boronophenylalanine (BPA). These new boronated drugs serve as effective vehicles for selectively delivering Boron to cancerous cells and augmenting the effectiveness of BNCT for many different cancer types.

 

BTS highlights:

• Targeted Delivery: BTS offers enhanced solubility, improved Boron delivery and retention within cancer cells.

• Boron Enrichment: The boronated compounds within BTS optimize the capture of neutrons, facilitating the destruction of cancer cells with precision.

• Therapeutic Advancement: BTS represents a paradigm shift in cancer therapeutics, heralding a new era of personalized, targeted treatment strategies.

 

Revolutionizing Cancer Care with BNCT:

By synergizing Alphabeam's precision neutron beam technology with targeted boronated drugs like BTS, TAE Life Sciences is spearheading the modernization of BNCT. This holistic approach aims to provide unparalleled precision, efficacy, and safety in cancer treatment.

 

Future Initiatives and Impact:

TAE Life Sciences is committed to advancing BNCT and continually innovating to broaden its therapeutic applications. With ongoing research and strategic collaborations, the company aims to expand its portfolio of boronated drugs, improve treatment protocols, and extend BNCT's reach across various cancer types.

 

Today, TAE Life Sciences shines as a beacon of hope in the fight against cancer. The company is determined to redefine treatment methods and usher in a new era of personalized and precise oncological care by launching clinical trials across America, Europe, and Asia.